Sera Antibody Repertoire Analyses Reveal Mechanisms of Broad and Pandemic Strain Neutralizing Responses after Human Norovirus Vaccination.
Amino Acid Sequence
Animals
Antibodies, Neutralizing
/ immunology
Antibodies, Viral
/ chemistry
Caliciviridae Infections
/ epidemiology
Cell Line
Conserved Sequence
Epitopes
/ chemistry
Humans
Immunoglobulin G
/ immunology
Models, Molecular
Norovirus
/ classification
Protein Binding
Protein Conformation
Recombinant Proteins
/ immunology
Vaccination
Viral Vaccines
/ immunology
antigenic seniority
epitope mapping
human monoclonal antibodies
imprinting
neutralizing antibodies
norovirus
original antigen sin
serological repertoire
vaccination
x-ray crystallography
Journal
Immunity
ISSN: 1097-4180
Titre abrégé: Immunity
Pays: United States
ID NLM: 9432918
Informations de publication
Date de publication:
18 06 2019
18 06 2019
Historique:
received:
03
01
2019
revised:
15
03
2019
accepted:
15
05
2019
entrez:
20
6
2019
pubmed:
20
6
2019
medline:
2
11
2019
Statut:
ppublish
Résumé
Rapidly evolving RNA viruses, such as the GII.4 strain of human norovirus (HuNoV), and their vaccines elicit complex serological responses associated with previous exposure. Specific correlates of protection, moreover, remain poorly understood. Here, we report the GII.4-serological antibody repertoire-pre- and post-vaccination-and select several antibody clonotypes for epitope and structural analysis. The humoral response was dominated by GII.4-specific antibodies that blocked ancestral strains or by antibodies that bound to divergent genotypes and did not block viral-entry-ligand interactions. However, one antibody, A1431, showed broad blockade toward tested GII.4 strains and neutralized the pandemic GII.P16-GII.4 Sydney strain. Structural mapping revealed conserved epitopes, which were occluded on the virion or partially exposed, allowing for broad blockade with neutralizing activity. Overall, our results provide high-resolution molecular information on humoral immune responses after HuNoV vaccination and demonstrate that infection-derived and vaccine-elicited antibodies can exhibit broad blockade and neutralization against this prevalent human pathogen.
Identifiants
pubmed: 31216462
pii: S1074-7613(19)30227-4
doi: 10.1016/j.immuni.2019.05.007
pmc: PMC6591005
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Epitopes
0
Immunoglobulin G
0
Recombinant Proteins
0
Viral Vaccines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1530-1541.e8Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 203268/Z/16/Z
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : R56 AI106006
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI109761
Pays : United States
Informations de copyright
Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.
Références
PLoS Pathog. 2012;8(7):e1002802
pubmed: 22829765
Nat Med. 2003 May;9(5):548-53
pubmed: 12692541
Nat Med. 2016 Dec;22(12):1456-1464
pubmed: 27820605
Cell Rep. 2017 Jan 3;18(1):237-247
pubmed: 28052253
Immunity. 2018 Apr 17;48(4):799-811.e9
pubmed: 29669253
mSphere. 2018 Feb 7;3(1):
pubmed: 29435493
J Virol. 2007 Sep;81(18):9932-41
pubmed: 17609280
J Infect Dis. 2014 Dec 1;210(11):1755-62
pubmed: 24970849
mSphere. 2017 Oct 18;2(5):
pubmed: 29062895
J Infect Dis. 2015 Mar 15;211(6):870-8
pubmed: 25210140
J Virol. 2011 Sep;85(17):8635-45
pubmed: 21715503
Emerg Infect Dis. 2008 Aug;14(8):1224-31
pubmed: 18680645
J Virol. 2014 Aug;88(16):8826-42
pubmed: 24872579
J Virol. 2004 Jun;78(12):6469-79
pubmed: 15163740
PLoS Pathog. 2012;8(5):e1002705
pubmed: 22615565
J Clin Microbiol. 2017 Jul;55(7):2208-2221
pubmed: 28490488
PLoS Med. 2015 Mar 24;12(3):e1001807
pubmed: 25803642
J Clin Microbiol. 1993 Aug;31(8):2185-91
pubmed: 8396590
J Med Virol. 2015 Apr;87(4):675-82
pubmed: 25655810
J Virol. 2012 Jan;86(2):1214-26
pubmed: 22090110
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
Viruses. 2019 Feb 20;11(2):
pubmed: 30791623
J Infect Dis. 2014 Dec 1;210(11):1763-71
pubmed: 24951828
N Engl J Med. 2011 Dec 8;365(23):2178-87
pubmed: 22150036
Sci Immunol. 2017 Jan 27;2(7):
pubmed: 28783671
J Infect Dis. 2017 Mar 15;215(6):984-991
pubmed: 28453838
Sci Transl Med. 2018 Jul 4;10(448):
pubmed: 29973404
Science. 1999 Oct 8;286(5438):287-90
pubmed: 10514371
J Infect Dis. 2018 Jan 30;217(4):597-607
pubmed: 29140444
J Virol. 2002 Dec;76(23):12335-43
pubmed: 12414974
J Gen Virol. 2007 Dec;88(Pt 12):3347-59
pubmed: 18024905
J Virol. 2013 Mar;87(5):2803-13
pubmed: 23269783
PLoS One. 2012;7(4):e35497
pubmed: 22558161
Methods Enzymol. 1997;276:307-26
pubmed: 27754618
J Mol Biol. 1999 Jan 29;285(4):1711-33
pubmed: 9917407
J Clin Microbiol. 1995 Jun;33(6):1452-5
pubmed: 7650166
J Virol. 2012 Apr;86(7):3635-46
pubmed: 22278249
Curr Opin Infect Dis. 2018 Oct;31(5):422-432
pubmed: 30102614
Lancet Infect Dis. 2017 Sep;17(9):909-948
pubmed: 28579426
Cell Host Microbe. 2016 Jun 8;19(6):800-13
pubmed: 27281570
J Infect Dis. 2019 Apr 16;219(9):1364-1372
pubmed: 30445538
J Infect Dis. 2018 Mar 13;217(7):1145-1152
pubmed: 29281104
J Virol. 2012 Jan;86(2):873-83
pubmed: 22090098
Expert Rev Vaccines. 2017 Jul;16(7):1-14
pubmed: 28562111
Curr Opin Virol. 2018 Aug;31:59-65
pubmed: 29857940
Nat Med. 2015 Jan;21(1):86-91
pubmed: 25501908
Proc Natl Acad Sci U S A. 2016 May 10;113(19):E2636-45
pubmed: 27114511
Virology. 2006 Mar 15;346(2):312-23
pubmed: 16343580
J Mol Biol. 2007 Sep 21;372(3):774-97
pubmed: 17681537
Nature. 2011 Nov 23;480(7377):336-43
pubmed: 22113616
J Virol. 2014 Jul;88(13):7256-66
pubmed: 24741081
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32
pubmed: 15572765
PLoS Pathog. 2017 Aug 30;13(8):e1006601
pubmed: 28854233
Front Immunol. 2014 Mar 19;5:96
pubmed: 24678310
J Med Virol. 2011 Mar;83(3):525-31
pubmed: 21264875
J Virol. 2011 Jul;85(13):6687-701
pubmed: 21525337
Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):2259-64
pubmed: 24469811
Science. 2011 Dec 2;334(6060):1289-93
pubmed: 22033520
Emerg Infect Dis. 2018 Aug;24(8):1453-1464
pubmed: 30014841
Gastroenterology. 2018 Dec;155(6):1898-1907
pubmed: 30170116
Nat Biotechnol. 2014 Feb;32(2):158-68
pubmed: 24441474
Curr Protoc Microbiol. 2013 Nov 05;31:15K.1.1-15K.1.45
pubmed: 24510290
J Virol. 2015 Feb;89(4):2024-40
pubmed: 25428879
Proc Natl Acad Sci U S A. 2011 Jan 4;108(1):325-30
pubmed: 21173246
Science. 2016 Sep 23;353(6306):1387-1393
pubmed: 27562956
Proc Natl Acad Sci U S A. 2016 Oct 4;113(40):E5830-E5837
pubmed: 27647885
Nucleic Acids Res. 2010 Jul;38(Web Server issue):W555-62
pubmed: 20478824
Science. 2016 Nov 11;354(6313):722-726
pubmed: 27846599
Helicobacter. 2015 Aug;20(4):260-8
pubmed: 25704078
J Infect Dis. 2010 Oct 15;202(8):1212-8
pubmed: 20815703
Vaccine. 2006 Jun 12;24(24):5220-34
pubmed: 16650512
PLoS Pathog. 2012;8(10):e1002921
pubmed: 23093932
PLoS Med. 2008 Feb;5(2):e31
pubmed: 18271619
J Virol. 2002 Mar;76(6):3023-30
pubmed: 11861868
J Appl Crystallogr. 2007 Aug 1;40(Pt 4):658-674
pubmed: 19461840
Vaccine. 2012 May 21;30(24):3580-6
pubmed: 22469864
Clin Infect Dis. 2014 Jun;58(12):1746-52
pubmed: 24585561
Bioinformatics. 2001 Aug;17(8):700-12
pubmed: 11524371
Cell Rep. 2018 Feb 13;22(7):1798-1809
pubmed: 29444432
Nat Protoc. 2016 Mar;11(3):429-42
pubmed: 26844430
PLoS One. 2012;7(5):e35791
pubmed: 22606235
J Synchrotron Radiat. 2004 Jan 1;11(Pt 1):53-5
pubmed: 14646133
Trends Microbiol. 2011 Aug;19(8):382-8
pubmed: 21705222
Infect Dis Clin North Am. 2017 Dec;31(4):839-870
pubmed: 28911830
J Clin Virol. 2018 Aug;105:1-10
pubmed: 29804008
J Virol. 2019 Feb 19;93(5):
pubmed: 30541855
J Virol. 2018 May 14;92(11):
pubmed: 29540599